Lily Colahan's corporate practice includes advising public and private companies in a broad array of business activities and transactions, with a focus on the technology and life sciences sectors.

Download full bio 

Experience

  • Molecular Partners – $64 Million IPO 

  • Centessa Pharmaceuticals – $380 Million IPO 

  • Edgewise Therapeutics – $202 Million IPO 

  • 908 Devices – $150 Million IPO 

  • Oncorus – $98 Million IPO 

  • View all

Education

  • Fordham University School of Law
    JD, magna cum laude, 2014

  • Tufts University
    BA, 2011


Admissions & Credentials

Massachusetts

New York

Media & Insight